Gilead Sciences

Gilead Sciences is a biopharmaceutical company built on antiviral therapies, with a dominant position in HIV treatment and prevention, a large hepatitis franchise and a growing presence in oncology through acquisitions such as Kite and Immunomedics. Its cash generation rests heavily on the durability of its HIV portfolio and its ability to renew the pipeline. Gilead began paying a dividend in the early 2010s and has raised it steadily since, funded by strong pharmaceutical margins and free cash flow. The yield is moderate and coverage comfortable, though the payout history is measured in years rather than decades and future growth depends on offsetting patent expirations. It offers a solid, growing dividend backed by a cash-rich biopharma, with the usual pipeline and patent risks attached.